Skip to main content
SpringerLink
Log in

Panic disorder

  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

In this article, the authors review the most recent advances in the pharmacotherapy, psychotherapy, and combined therapy for panic disorder. The authors focus on peerre-viewed data and on pragmatic clinical approaches that may help patients suffering from panic disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Eaton WW, Kessler RC, Wittchen HU, Magee WJ: Panic and panic disorder in the United States. Am J Psychiatry 1994, 151:413–420.

    PubMed  CAS  Google Scholar 

  2. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8–9.

    PubMed  CAS  Google Scholar 

  3. Myers JK, Weissman MM, Tischler GL, et al.: Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry 1984, 41:959–967.

    PubMed  CAS  Google Scholar 

  4. Weissman MM, Merikangas KR: The epidemiology of anxiety and panic disorders: an update. J Clin Psychiatry 1986, 47(suppl):11–17.

    PubMed  Google Scholar 

  5. Klein D: Delineation of two-drug responsive anxiety syndromes. Psycopharmacologia 1964, 5:397–408.

    Article  CAS  Google Scholar 

  6. Klein D, Fink M: Psychiatric reaction patterns to imipramine. Am J Psychiatry 1962, 119:432–438.

    PubMed  CAS  Google Scholar 

  7. Pollack MH, Otto MW, Rosenbaum JF, et al.: Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 1990, 51(suppl):12–16.

    PubMed  Google Scholar 

  8. Pollack MH, Otto MW, Worthington JJ, et al.: Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998, 55:1010–1016.

    Article  PubMed  CAS  Google Scholar 

  9. Rapaport MH, Cantor JJ: Panic disorder in a managed care environment. J Clin Psychiatry 1997, 58(suppl)2:51–55.

    PubMed  Google Scholar 

  10. Klein DF: Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 2000, 157:1204–1211.

    Article  PubMed  CAS  Google Scholar 

  11. Barlow DH, Gorman JM, Shear MK, Woods SW: Cognitivebehavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000, 283:2529–2536. A good article.

    Article  PubMed  CAS  Google Scholar 

  12. Shear MK, Maser JD: Standardized assessment for panic disorder research. A conference report. Arch Gen Psychiatry 1994, 5:346–354.

    Google Scholar 

  13. Londborg PD, Wolkow R, Smith WT, et al.: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998, 173:54–60.

    PubMed  CAS  Google Scholar 

  14. Rapaport MH, Wolkow RM, Clary CM: Methodologies and outcomes from the sertraline multicenter flexible-dose trials. Psychopharmacol Bull 1998, 34:183–189.

    PubMed  CAS  Google Scholar 

  15. Lecrubier Y, Bakker A, Dunbar G, Judge R: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997, 95:145–152.

    PubMed  CAS  Google Scholar 

  16. Ballenger JC, Wheadon DE, Steiner M, et al.: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998, 155:36–42.

    PubMed  CAS  Google Scholar 

  17. Wade AG, Lepola U, Koponen HJ, et al.: The effect of citalopram in panic disorder. Br J Psychiatry 1997, 170:549–553.

    Article  PubMed  CAS  Google Scholar 

  18. Michelson D, Lydiard RB, Pollack MH, et al.: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998, 155:1570–1577.

    PubMed  CAS  Google Scholar 

  19. Hoehn-Saric R, McLeod DR, Hipsley PA: Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993, 13:321–326.

    Article  PubMed  CAS  Google Scholar 

  20. Rickels K, Schweizer E: Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998, 18(suppl):12S-18S.

    Article  PubMed  CAS  Google Scholar 

  21. Moroz G, Rosenbaum JF: Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999, 60:604–612.

    Article  PubMed  CAS  Google Scholar 

  22. Worthington JJ, III, Pollack MH, Otto MW, McLean RY, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull 1998; 34(2):199–205.

    PubMed  CAS  Google Scholar 

  23. Schweizer E, Fox I, Case G, Rickels K: Lorazepam vs. alprazolam in the treatment of panic disorder. Psychopharmacol Bull 1988, 24:224–227.

    PubMed  CAS  Google Scholar 

  24. Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995, 10:45–49.

    Article  PubMed  CAS  Google Scholar 

  25. Kalus O, Asnis GM, Rubinson E, et al.: Desipramine treatment in panic disorder. J Affect Disord 1991, 21:239–244.

    Article  PubMed  CAS  Google Scholar 

  26. Lydiard RB, Morton WA, Emmanuel NP, et al.: Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 1993, 29:183–188.

    PubMed  CAS  Google Scholar 

  27. Munjack DJ, Usigli R, Zulueta A, et al.: Nortriptyline in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1988, 8:204–207.

    Article  PubMed  CAS  Google Scholar 

  28. den Boer JA: Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry 1998, 59(suppl 8):30–36.

    Google Scholar 

  29. Cassano GB, Petracca A, Perugi G, et al.: Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988, 14:123–127.

    Article  PubMed  CAS  Google Scholar 

  30. Modigh K, Westberg P, Eriksson E: Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992, 12:251–261.

    Article  PubMed  CAS  Google Scholar 

  31. Sasson Y, Iancu I, Fux M, et al.: A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999, 9:191–196.

    Article  PubMed  CAS  Google Scholar 

  32. Noyes R, Jr., Garvey MJ, Cook BL: Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord 1989, 16:249–257.

    Article  PubMed  Google Scholar 

  33. Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980, 37:51–59.

    PubMed  CAS  Google Scholar 

  34. Bakish D: Reversible monoamine-A inhibitors in panic disorder. Clin Neuropharmacol 1992, 15(suppl):432A-433A.

    PubMed  Google Scholar 

  35. Tiller JW, Bouwer C, Behnke K: Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 1999, 249(suppl):S7–10.

    Article  PubMed  Google Scholar 

  36. van Vliet IM, Westenberg HG, den Boer JA: MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology (Berl) 1993, 112:483–489.

    Article  Google Scholar 

  37. Carpenter LL, Leon Z, Yasmin S, Price LH: Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999, 11:81–86.

    Article  PubMed  CAS  Google Scholar 

  38. Falkai P: Mirtazapine: other indications. J Clin Psychiatry 1999, 60(suppl):36–40.

    Article  PubMed  CAS  Google Scholar 

  39. DeMartinis NA, Schweizer E, Rickels K: An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996, 57:245–248.

    PubMed  CAS  Google Scholar 

  40. Pollack MH, Worthington JJ, III, Otto MW, et al.: Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996, 32:667–670.

    PubMed  CAS  Google Scholar 

  41. Leinonen E, Skarstein J, Behnke K, et al.: Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999, 14:329–337.

    Article  PubMed  CAS  Google Scholar 

  42. Sheehan DV, Davidson J, Manschreck T, Van Wyck FJ: Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983, 3:28–31.

    Article  PubMed  CAS  Google Scholar 

  43. van Vliet IM, Westenberg HG, den Boer JA: Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl) 1996, 127:174–180.

    Article  Google Scholar 

  44. Gastfriend DR, Rosenbaum JF: Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. Am J Psychiatry 1989, 146:914–916.

    PubMed  CAS  Google Scholar 

  45. Bradwejn J, Koszycki D: The cholecystokinin hypothesis of anxiety and panic disorder. Ann N Y Acad Sci 1994, 713:273–282.

    Article  PubMed  CAS  Google Scholar 

  46. Kramer MS, Cutler NR, Ballenger JC, et al.: A placebocontrolled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 1995, 37:462–466.

    Article  PubMed  CAS  Google Scholar 

  47. Pande AC, Greiner M, Adams JB, et al.: Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 1999, 46:860–862.

    Article  PubMed  CAS  Google Scholar 

  48. Woodman CL, Noyes RJr: Panic disorder: treatment with valproate. J Clin Psychiatry 1994, 55:134–136.

    PubMed  CAS  Google Scholar 

  49. Keck PE, Jr., Taylor VE, Tugrul KC, et al.: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993, 33:542–546.

    Article  PubMed  Google Scholar 

  50. Etxebeste M, Aragues E, Malo P, Pacheco L: Olanzapine and panic attacks [letter]. Am J Psychiatry 2000, 157:659–660.

    Article  PubMed  CAS  Google Scholar 

  51. Barlow DH, Lehman CL: Advances in the psychosocial treatment of anxiety disorders. Implications for national health care. Arch Gen Psychiatry 1996, 53:727–735.

    PubMed  CAS  Google Scholar 

  52. Telch MJ, Lucas JA, Schmidt NB, et al.: Group cognitivebehavioral treatment of panic disorder. Behav Res Ther 1993, 31:279–287.

    Article  PubMed  CAS  Google Scholar 

  53. Dyckman JM, Rosenbaum RL, Hartmeyer RJ, Walter LJ: Effects of psychological intervention on panic attack patients in the emergency department. Psychosomatics 1999, 40:422–427.

    PubMed  CAS  Google Scholar 

  54. Wade WA, Treat TA, Stuart GL: Transporting an empirically supported treatment for panic disorder to a service clinic setting: a benchmarking strategy. J Consult Clin Psychol 1998, 66:231–239.

    Article  PubMed  CAS  Google Scholar 

  55. Stuart GL, Treat TA, Wade WA: Effectiveness of an empirically based treatment for panic disorder delivered in a service clinic setting: 1-year follow-up. J Consult Clin Psychol 2000, 68:506–512. A good review.

    Article  PubMed  CAS  Google Scholar 

  56. Newman MG, Kenardy J, Herman S, Taylor CB: Comparison of palmtop-computer-assisted brief cognitive-behavioral treatment to cognitive-behavioral treatment for panic disorder. J Consult Clin Psychol 1997, 65:178–183.

    Article  PubMed  CAS  Google Scholar 

  57. Black DW, Wesner R, Bowers W, Gabel J: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993, 50:44–50.

    PubMed  CAS  Google Scholar 

  58. Clark DM, Salkovskis PM, Hackmann A, et al.: Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol 1999, 67:583–589.

    Article  PubMed  CAS  Google Scholar 

  59. Spiegel DA, Bruce TJ, Gregg SF, Nuzzarello A: Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry 1994, 151:876–881.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of California at San Diego and Psychiatric Service San Diego Veterans Affairs Healthcare System, 8950 La Jolla Drive, 92037, La Jolla, CA, USA

    Mark Hyman Rapaport MD & Cristin Barrett BS

Authors
  1. Mark Hyman Rapaport MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristin Barrett BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rapaport, M.H., Barrett, C. Panic disorder. Curr Psychiatry Rep 3, 295–301 (2001). https://doi.org/10.1007/s11920-001-0022-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-001-0022-1

Keywords

Search

Navigation